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PENYIASATAN MEKANISME MOLEKUL YANG MENDASARI 
AKTIVITI ANTI-TUMOR DAN ANTI-ANGIOGENIK 
ORTHOSIPHON STAMINEUS TERHADAP KANSER USUS 
ABSTRAK 
 
Teh Orthosiphon stamineus Benth. (Lamiaceae) digunakan secara meluas 
dalam perubatan tradisional. Kajian terbaru menunjukkan bahawa 50% ekstrak 
ethanolik daripada Orthosiphon stamineus (EOS) dan sebatian aktif, asid rosmarinik 
(RA), memaparkan kesan-kesan anti-angiogenik, anti-radang dan anti-tumor yang 
ketara dalam pelbagai model eksperimen. Walau bagaimanapun, mekanisme yang 
mendasari sifat-sifat ini tidak dinilai dengan sepenuhnya. Kajian yang dijalankan ini 
bertujuan untuk menilaikan lagi mekanisme molekul yang mendasari anti-tumor dan 
anti-angiogenik. Dalam model eksperimen penghijrahan, perkembangan dan 
pembentukan tiub, cerakin kedua-dua EOS dan RA aktif menyebabkan perencatan 
ketara terhadap fungsi sel endothelial manusia (HUVECs) yang penting bagi 
merangsang proses angiogenesis. Dalam kedua-dua kajian in vitro dan in vivo, 
penindasan besar neovaskularisasi dalam model aorta tikus, CAM dan plug matrigel 
juga diperhatikan. Kajian cerakin multipleks menunjukkan pengurangan faktor 
pertumbuhan utama bagi lata pro-angiogenik dan perkembangan tumor iaitu faktor 
pertumbuhan endothelial vaskular (VEGF), faktor pertumbuhan fibroblast asas (b-
FGF), transformasi faktor pertumbuhan transformasi (TGF-α), faktor nekrosis tumor 
(TNF-β) dan interleukin-1, 2, 7. Induksi terhadap agen anti-tumor iaitu interferon 
(IFN-α, β) dan faktor perangsang koloni makrofaj granulosit (GM-CSF)  secara in 
vitro dan in vivo juga diperhatikan. EOS dan RA juga menyebabkan penurunan yang 
ketara perantara-perantara radang pro-angiogenik, enzim cyclooxygenase (COX), 
TNF-α, IL-1 dan tahap nitrik oksida (NO) yang penting untuk tumorigenesis. Lebih-
xxxiii 
 
lebih lagi, EOS dan RA telah menghalang expresi gen secara signifikan dalam tisu 
tumor usus termasuk HIF-α, WNT, KDR dan COX2. Tambahan pula, EOS 
menghalang mercu tanda metastasis secara meluas iaitu pencerobohan dan 
pengagregatan tumor yang dibuktikan secara tomografi pendarfluor molekul (FMT) 
melalui pengimejan in vivo dan analisis histopatologi. Penemuan ini bertepatan 
dengan kesan rencatan pada tumor penggalak faktor angiogenesis dalam model 
mencit xenograft. Simulasi interaksi molekular dalam silico terhadap penanda 
biologi aktif EOS mengesahkan pertalian pengikat baik dan kesan modulatori kukuh 
terhadap faktor angiogenik dan tumorigenik. Ia mungkin disebabkan oleh kandungan 
fenolik dan flavonoid yang tinggi dalam EOS turut mengenakan kesan anti-tumor 
yang signifikan melalui modulasi pro-radang dan pengantara-pengantara 
angiogenesis melalui kesan hapus-sisa radikal bebas yang ketara. Kesimpulannya, 
hasil keseluruhan menyokong dan mengesahkan bahawa sifat-sifat anti-angiogenik 
dan anti-tumor EOS dan RA dibuktikan melalui kesan pemodulasian signifikan 
terhadap faktor-faktor utama pertumbuhan dan perantara. 
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INVESTIGATION OF MOLECULAR MECHANISMS 
UNDERLYING THE ANTI-TUMOR AND ANTI-ANGIOGENIC 
ACTIVITIES OF ORTHOSIPHON STAMINEUS TOWARDS 
COLORECTAL CANCER 
ABSTRACT 
 
Orthosiphon stamineus Benth. (Lamiaceae) tea is widely consumed 
traditionally for its vast medicinal value. Recent studies revealed that 50% ethanolic 
extract of Orthosiphon stamineus (EOS) and its active compound, rosmarinic acid 
(RA), displayed significant anti-angiogenic, anti-inflammatory and anti-tumor effects 
in various experimental models. However, the mechanisms underlying these 
properties have not been fully evaluated. The present work aims to further evaluate 
the molecular mechanisms underlying its anti-tumour and anti-angiogenic properties. 
In migration, proliferation and tube formation assay, both EOS and its active RA 
caused significant inhibition of human endothelial cell (HUVECs) functions crucial 
for promotion of angiogenesis.  Both in vitro and in vivo studies revealed significant 
suppression of neovascularisation in rat aortic ring, CAM and matrigel plug. 
Multiplex array studies showed reduction of key growth factors for pro-angiogenic 
cascade and tumor development i.e. Vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (b-FGF), transforming growth factor alpha (TGF-α), 
tumor necrosis factor (TNF-β) and interleukin-1, 2, 7. Induction of anti-tumor agents 
i.e. interferon (IFN-α, β) and granulocyte macrophage colony stimulating factor 
(GM-CSF) both in vitro and in vivo was also noted. In addition, EOS and RA also 
caused a marked reduction of pro-angiogenic inflammatory mediators, 
cyclooxygenase (COX) enzyme, TNF-α, IL-1 and nitric oxide (NO) level vital for 
tumorigenesis. Moreover, EOS and RA significantly inhibited the genes expression 
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in colorectal tumor tissue including HIF-α, WNT, KDR and COX2. Furthermore, 
EOS extensively inhibited invasion and tumor aggregation evidenced by fluorescent 
molecular tomography (FMT) in vivo imaging and histopathological analysis. These 
findings coincide with its inhibitory effects on tumor promoting angiogenesis factors 
in nude mice xenograft. In silico molecular interaction simulations on EOS active 
biomarkers confirms good binding affinity and strong modulatory effect towards the 
angiogenic and tumorigenesis factors. It is likely the high phenolic and flavonoids 
content in EOS also exert a significant anti-tumor effect via modulating pro-
inflammatory and angiogenesis mediators through their significant free radicals 
scavenging effect. In conclusion, overall results strongly substantiates EOS and RA 
anti-angiogenic and anti-tumor properties evidenced by their significant modulatory 
effect on key associated growth-factors and mediators. 
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CHAPTER ONE 
 
1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Cancer 
Cancer is a malignant disease, which affects different parts of the body 
resulting in pathologic changes, genetic and epigenetic disorders factors which may 
act together or in sequence to cause cancer. Cancer occurs when groups of normal 
cells grow abnormally fast, losing control of cell division or with slow cell death 
(apoptosis) consequently, transformed from normal cells into malignant cells 
(Vanhoecke et al., 2005; Giansanti et al., 2011). Cancer is not a single disease but 
syndrome which comprises of group of multiple diseases. There are more than 100 
various types of cancer that are named according to the sites where a cancerous 
growth originates. 
The cancer cells are characterized by their invasion of the nearby tissue and 
spreading through the blood stream and lymphatic system to other organs or tissue 
(metastasis) (Zhong and Bowen, 2006). Cancer that initiates in the organs such as 
breast is called breast cancer and cancer that starts in the lung is called lung cancer 
and so on. 
Metastasis is the final step of cancer and the major cause of death resulting 
from cancer. Bone metastases are the most common cause of cancer pain. Usually, 
under normal conditions, cells grow and divided automatically in order to replace the 
damaged cells or produce new cells. At times this orderly process goes wrong 
probably due to problem with the genetic material (DNA). Mutations are generally 
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caused by internal or external cellular damage and thereby the normal cells are 
converted into malignant cells. To date, the resistance of cancer cells towards cancer 
therapy has recognized one of the major problems in treating the disease hence much 
research been made towards the understanding of cancer biology and treatment using 
advanced protocols like radiotherapy and chemotherapy. There are two types of 
tumors, classified based on their growth and spread. Tumors that do not spread to 
other parts of the body and are incapable of recurrence are referred to as benign 
tumors. However, tumors are called malignant when a tumor cell invades the 
surrounding tissues and spreads to other parts of the body (Hanahan and Weinberg, 
2011). 
1.1.1 Cancer epidemiology 
Cancer is a major public health problem and the second killer disease after 
cardiovascular diseases which cause of illness and mortality worldwide. In 2002, an 
estimated 10.9 million new cases of cancer incidence and mortality were reported 
globally with 6.7 million deaths (Parkin et al., 2005). In 2013, Bray reported that 
about 29 million people were living with cancer (Bray et al., 2013) and there were an 
estimated 7.6 million deaths (13% of all deaths) in 2008 (Gutschner and Diederichs, 
2012).  
World Health Organization (WHO) reported that cancer incidence and 
cancer-related mortality has increased remarkably, with 14 million new cases and 8.2 
million deaths in 2012. Among all the cancers, the five most commonly diagnosed 
cancers in men were lung cancer, followed by prostate, colorectal, stomach, and liver 
cancers. While for women, the five most commonly diagnosed cancers were breast, 
followed by colorectal, lung, cervix, and stomach cancers. In general, the most 
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frequent source of cancer death was lung cancer with an estimated mortality rate of 
1.59 million cases followed by liver cancer with 745,000 cases, stomach cancer with 
723,000 cases, colorectal cancer with 694,000 cases, breast cancer with 521,000 
cases and oesophageal cancer with 400,000 cases. Incidence, morbidity and mortality 
of cancer is expected to rise by more than 70% in the next two decades, which means 
that the incidence of cancer cases will increased from 14.1 million in 2012 to 22 
million within the next two decades (Organization, 2014). 
 Incident rate of cancer in more developed areas was highest compared with 
the least developed areas. On the other hand, the mortality cases were much higher in 
less developed region, because of the economic costs, lack of diagnosis, late 
detection and treatment (Torre et al., 2015). Incidences of cancer have been on rise in 
both developed and developing countries.  
Cancer is the main cause of death among adults aged 40 to 79 years and is the 
first or second leading cause of death in every age group among women (Boffetta 
and Parkin, 1994; Siegel et al., 2015). In 2015, it is estimated that 1,658,370 new 
cancer cases will be diagnosed and 589,430 cancer deaths in the USA (Siegel et al., 
2015). However, overall cancer death rates decreased in 2011 with 168.7 per 100,000 
populations from 215.1 (per 100,000 populations) in 1991. The 22% decrease in 
cancer deaths from 1991 to 2011 was a result of early detection, decrease in 
smoking, new drugs and treatment. Advances in cancer prevention approaches have 
also been introduced (Siegel et al., 2015).  
According to the third edition of International Classification of Diseases for 
Oncology (ICD-O), cancer can be divided into five categories based on the primary 
and initial tumor, as bellow; 
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a) Carcinoma starts in tissue that covers the internal organs or epithelial cell; it 
can be grouped into different subtypes such as, adenocarcinoma, squamous cell 
carcinoma, transitional carcinoma and basal cell carcinoma.  
b) Lymphoma and myeloma that start in the cells of the immune system 
c) Leukemia progresses in blood formation tissue like bone marrow. 
d) Central nervous system cancers are cancers that originate in the tissues of the 
spinal cord and brain.  
e) Sarcoma is initiated in cartilage, bone, blood vessels, fat, connective tissue and 
muscle (Fritz et al., 2000) 
1.1.2 Cancer in Malaysia 
In 2008, the WHO‟s Globocan reported that cancer is one of the leading 
causes of death in Malaysia with an estimate of 30,000 annual cases. Based on the 
latest health facts 2013 reported by the Ministry of Health (MoH) of Malaysia, the 
incidence of cancer in Malaysia increased from 32,000 new cases in 2008 to 37,400 
in 2012. This number may be expected to increase to 56,932 by 2025, if no proper 
prevention strategy or good lifestyle.  
Breast cancer is the most common cancer among Malaysian followed by 
colorectal and lung cancer, with one in 19 Malaysians developing breast cancer, one 
in 33 developing colorectal cancer and one in 40 developing lung cancers. For men, 
lung cancer is the most frequent cancer followed by cancer of nasopharynx, colon, 
leukaemia, rectum and prostate. In women, the most frequent cancers are that of the 
breast followed by cervix, colon, ovary, leukaemia and lung (Lim et al., 2002). 
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1.1.3 Development and progression of cancer 
To date, the causes of cancer are not completely understood. Cancer originates from 
single a mutated cell which starts to divides in uncontrolled manner exceeding 
normal cells, these aggressively proliferating cells can invade and destroy 
neighboring tissues and may spread to other parts of the body (metastasis), unlike 
normal cells which are self-regulated, restricted growth potential and on ability of 
metastasis. 
  The mutation may occur due to random genetic damage by endogenous 
factors, such as intrinsic chemicals of DNA bases, the abnormality or error in DNA 
replication which can be attributed to carcinogens such as infectious agent, 
chemicals, radiation, or free redials during metabolism (Ames, 1989; Hall and 
Angele, 1999; Bertram, 2000). The mutated cells grow fast until it form colony, these 
transformed cells divide more and more via altering the environment in a manner that 
favors  the growth mutated cells over normal cells.   
 The first stage of transformed cells is a group of highly divided cell with 
normal appearance (hyperplasia). More transformation to hyperplastic leads to 
abnormal looking cells (dysplasia). The next stage of the transformation of mutated 
cells cancerous may take between 5-20 years for the transition of benign 
carcinogenic phase to the fully developed malignant stage where the neoplasia can be 
detected clinically. 
 The last stage is termed as „progression‟, where further genetically changes 
take place resulting in the increase of proliferation and metastasis (Marshall, 1991; 
Weinberg, 1996; Compagni and Christofori, 2000; Kintzios and Barberaki, 2004) . 
Genetic change (mutations) and external factors react together in sequence and target 
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two groups of normal regulatory genes (proto-oncogenes and tumor suppressor 
gene), which transfer to the cancer causing gene. Proto-oncogenes are genes encode 
proteins that are found in every cell, which stimulate cell proliferation, differentiation 
and development (Sherr, 2004). This normally helps in cells homeostasis. The genes 
that activated by mutation are called oncogenes, which can be produced by six major 
factors: growth factors, transcription factor, growth factors receptors, chromatin 
remodelers, apoptosis regulation, and signal transducers factors (Croce, 2008) (Table 
1.1). In contrast, the gene of which the inhibition is by mutation is called the tumor-
suppressor gene (Table 1.2). Oncogenes accelerate the tumor cells when activated by 
mutation. The normal cell process is a balance between tumor-suppressor genes and 
oncogenes. Tumour-suppressor genes are normal genes which inhibit tumor 
formation by controlling the cell division, apoptosis and repair DNA mistakes that 
occur during DNA replication. They act as the “brakes” for the cell cycle. Tumor-
suppressor genes mutations lead to a growth of cancer by inactivating that inhibitory 
function of these genes. In addition, environment and lifestyle, including tobacco, 
obesity, infectious agents, alcohol, hyperglycemia, food carcinogens, sunlight, stress, 
and environmental pollutants are major causes of cancer which includes about 90-
95% of cases and the remaining 5-10% are due to genetic defects (Anand et al., 
2008). 
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Table ‎1.1:  List of oncogenes.  
Oncogenes Activation/function Cancer 
Abl  Promote cell growth through tyrosine 
kinase activity 
Chronic 
myelogenous  leukemia 
(Croce, 2008) 
Myb Transcription factor Colon carcinoma and 
leukemia 
Trk Receptor tyrosine kinase Colon and thyroid carcinomas 
C-myc A transcription factor that promotes 
cell proliferation and DNA synthesis 
Leukemia; breast,stomach,  
lung, cervical, and colon 
carcinomas; neuroblastomas 
and glioblastomas 
(Weber,1987) 
HER2/neu Over-expression of signalling kinase 
due to gene amplification 
Breast and cervical 
carcinomas (Weber,1987) 
Af4 / hrx Fusion affects the hrx transcription 
factor / methyltransferase 
Acute leukemias 
Akt-2 Encodes a protein-serine / threonine 
kinase 
Ovarian cancer 
KRAS promoting cell survival and apoptosis 
suppression 
colorectal carcinomas and 
lung cancer (Croce, 2008) 
Alk/npm Translocation creates a fusion 
protein with nuclear phosmin (npm) 
Large cell lymphomas 
Aml1 Encodes a transcription factor Acute myeloid leukemia 
Aml1/mtg8 A new fusion protein created by the 
translocation 
Acute leukemias 
Axl Encodes a receptor tyrosine kinase Hematopoietic cancers 
Bcl 2, 3, 6 Block apoptosis (programmed cell 
death) 
B-cell lymphomas and 
leukemias 
Dbl Guanine nucleotide exchange facto Diffuse B-cell lymphoma 
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Table ‎1.2: Some of tumor suppressor genes.  
Tumor 
suppressor genes 
Activation/function Cancer 
APC(denomatous 
polyposis coli) 
Signaling through adhesion 
molecules to the nucleus 
Colorectal carcinomas 
(Santos, 2009) 
BRCA1, BRCA2 DNA Damage Repair breast cancers; ovarian 
cancers (Yoshida, 2004) 
DCC Netrin-1 receptor. Regulation of 
cell proliferation and apoptosis of 
intestinal epithelium. 
Colorectal carcinomas 
DPC4 (SMAD4) Transcriptional factor involved in 
development; Implicated in 
metastasis and tumor invasiveness. 
Colorectal tumors, 
pancreatic neoplasia 
MADR2/JV18 
(SMAD2) 
Mediates signaling from growth 
factor receptors.  Assists in 
transport of SMAD4 into nucleus. 
Colorectal cancer 
MLH1&MSH2 DNA single-nucleotide mismatch-
repair defect permitting the 
accumulation of oncogenic 
mutations and tumor-suppressor 
loss 
Colorectal cancer      
(Sarrió, 2003) 
NF1 RAS GTPase activating protein 
(RAS-GAP) 
Neurofibromatosis type 1 
p53 Cell cycle regulation, apoptosis Bladder, breast, colorectal, 
esophageal, liver, lung, 
prostate, and ovarian 
carcinomas; brain tumors, 
sarcomas, lymphomas, and 
leukemias (Santos, 2009) 
RB Binds to, and inhibits, the E2F 
transcription factor.  Halts cell 
cycle progression 
Retinoblastoma, sarcomas; 
bladder, breast, esophageal, 
prostate, and lung 
carcinomas 
TGFBR2 Receptor responsible for signaling 
pathways mediating growth arrest 
and apoptosis 
Colorectal and ovarian 
cancer 
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1.1.4 Cancer pathology and genetic events of tumorigenesis 
In 2000, Hanahan and Weinberg proposed 10 main cellular procedures based 
on transformation and development of normal cells to establish malignant neoplastic 
tissue (Hanahan and Weinberg; 2000; Negrini et al., 2010; Hanahan and Weinberg, 
2011).These basic hallmarks capabilities acquired during tumor development are: 
1- Sustaining proliferatives signalling. This is one of the characterise of cancer cells, 
which can be acquired by various pathways and is defined by the cells ability to 
grow constantly without external signals and produce their own growth 
factors,and the corresponding receptor molecules by the autocrine proliferative 
stimulation. In addition, they stimulate normal cells and tumor-associated cells 
by producing paracrine signals, in order to support the cancer cells by forming 
different growth factors(Gutschner and Diederichs, 2012).  
2- Inducing angiogenesis, which activate quiescent endothelial cells in order to 
grow new blood cells. The growth and metastatic of tumors require the formation 
of new blood vessels. Therefore, during tumor development and progression the 
“angiogenic switch” is activated and maintained to support the neoplastic growth 
by suppling nutirient and oxygn throw the new blood vessels. Tumor cells 
activate the “angiogenic switch” by countervailing inhibitors, thus inducing and 
sustaining the angiogenesis substances will occur (Hanahan and Folkman, 1996).  
3- Evading growth suppressors (antigrowth).  
4- Resisting of programmed cell death (apoptosis). 
5- Limitless replication potential. Cancer cells know how to renew themselves 
continuously.  
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6- Enhancement tissue metastasis and invasion. Benign tumors are not harmful if 
they do not spread to other parts of the body. While the malignant tumor which 
invade surrounding tissues and spread to the other parts of the body (Hanahan 
and Weinberg, 2011). 
7- Genomic instability and mutation are characteristics of most of tumors which 
generate random mutations during DNA repair and drive tumor development 
(Negrini et al., 2010; Hanahan and Weinberg, 2011).  
8- Evading immune surveillance, in particular by T and B lymphocytes, 
macrophages, and natural killer cells. 
9- Tumor-promoting inflammation. 
10- Deregulating cellular energetic (Figure 1.1). 
 
Figure ‎1.1: Ten hallmarks of cancer acquired during cancer progression. Adapted 
from (Hanahan and Weinberg, 2011). 
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1.2 Colorectal cancer 
Colorectal cancer (CRC) is a multistep process of epithelial cells 
transformation into malignant cells, which is caused by the sequential order of 
genetic, growth factors and epigenetic mutations (Pancione et al., 2012). Several 
researchers have been reported that development and rise of colorectal tumors 
associated with specific mutation including microsatellite instability (MSI), 
adenomatous polypsis coli (APC) gene, stabilization and translocation of β-catenin, 
chromosomal instability (CIN), Kirsten-rat sarcoma virus (KRAS), TP53, loss of the 
18q21 gene cyclooxygenase-2 (COX-2), and mutations in transforming growth factor 
β II receptor (TGFβR2) (Markowitz and Bertagnolli, 2009; Kanthan et al., 2012) 
(Figure 1.2). 
 
Figure ‎1.2: Genetic alterations frequently associated with CRC progression 
Adapted from (Markowitz and Bertagnolli, 2009) 
Previous studies were illustrated the role of the APC suppressor gene in the 
early stages of colorectal carcinoma. Inactivation of APC gene is associated with 
accumulation of intracellular β-catenin which plays a central role in cell adhesion 
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and acts as a transcription factor of the Wnt signaling pathway (Yang et al., 2006). 
Stimulation of Wnt/β-catenin signaling pathway leads to activation of T-cell 
factor/lymphoid enhancing factor-1 (TCF/LEF1) transcription factors and 
subsequently to the expression of several target genes including COX-2, cyclin D1 
and c-Myc that are concerned in tumorigenesis of colorectal carcinoma and several 
other cancers (MacDonald et al., 2009). In addition, oncogenic mutations in K-ras 
were found to play essential role in tumorigenesis of colorectal carcinoma and their 
presence indicates poor prognosis (Conlin et al., 2005). Besides the hereditary APC 
alteration and other acquired genetic changes there are other associated genetics, 
enzymes and antigenic that have been found to play a central role in the adenoma-
carcinoma sequence. Various carcinogenic factors have been described which also 
contribute in the adenoma and carcinoma formation such as familial history of 
colonic neoplasia, acromegaly, ulcerative colitis, drinking, smoking and consumption 
of red meat.  
1.2.1 Epidemiology of colorectal cancer 
Colorectal cancer incidence in man is higher than women with an overall sex 
ratio of the age standard rate, of 1.4:1 (Ferlay et al., 2010). In man, it is the third 
most commonly diagnosed malignant neoplasm worldwide (663,000 cases, 10.0% of 
the total) (Siegel et al., 2015; Scholefield and Eng, 2014), and the second most 
common cancer in women (570,000 cases, 9.4% of the total), beside it is the third 
leading cause of cancer deaths, accounting for 600,000 deaths each year (Roper and 
Hung, 2013). In the United States, colorectal cancer is the third leading cause of 
cancer deaths (9% of estimated cancer deaths in both men and women in 2012) 
(Scholefield and Eng, 2014).  
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Globally, CRC is a burden; the incidence rate is ten times higher in regions 
with the highest rate, such as Australia and Canada than in regions with the lowest 
rates, such as India, while the mortality rate is five times higher in regions with the 
highest rates than it is in regions with the lowest rates (Scholefield and Eng, 2014). 
The American Cancer Society (ACS) estimates 132,700 new cases of colorectal 
cancer in women and men and that 49,700 will die as a result of it in the United 
States in 2015 (Smith et al., 2015), compared to the incidence 148,300 new cases and 
56,600 deaths in 2002. CRC is the second most common malignancy in Malaysia. 
Life styles, heredity, diet and micronutrient malnutrition are few putative etiology in 
CRC. The incidence of CRC is higher in Malaysia compared to incidence in Indian 
subcontinent possibly due to low intake of dietary insoluble fibre, higher animal diet 
and red meat content of food. The epidemiological data on CRC in Malaysia are 
fragmentary and insufficient. Moreover there is no specific control or preventive 
measure taken by ministry of health to detect CRC early in Malaysia. Colonoscopy 
and Fecal occult blood test are rarely advocate  for early detection. Therefore it is 
very rare to find CRC patients in early stages. The stage distribution of CRC patients 
in Malaysia is shifted to right with majority being presented in late stages (III & IV). 
In few earlier studies stage per stage survival of CRC are lower compared to western 
counterparts (Biswal et al., 2002). 
1.2.2 Chemotherapeutics of colorectal cancer 
Chemotherapy is a type of cancer treatment that uses one or more of medicinal 
drug to destroy the cancer cells. Up to know, no curative therapy is available for 
most types of cancer including colon cancer. The available treatments are used to 
prolong the life span of cancer patients. Previously, cytotoxic agents such as 5-
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fluorouracil (5-FU), oxaliplatin (OX) and capecitabine (Cap) were used to treat 
colorectal cancer. The various combinations of these agents were extensively studied 
in phase II and phase III clinical trials such as IFL (irinotecan, 5-FU and LV), 
FOLFOX (5-FU, OX and LV), FOLFIRI (5-FU, LV and irinotecan) and CapOx 
(capecitabine/oxaliplatin). All of these combinations showed improvement in the 
therapeutic outcome than with mono-therapy (Cercek and Saltz, 2008). After the 
development of the monoclonal antibodies bevacizumab (anti-VEGF), panitumumab 
(human anti-EGFR) and Cetuximab (chimeric human-mouse anti-EGFR), several 
combinations of these agents, with the cytotoxic drugs have been studied in phase II 
and phase III clinical trials. In general, the results show that the combination of anti-
angiogenic factors either anti-VEGF or anti-EGFR antibodies with cytotoxic agents 
resulted in increased therapeutic outcomes than each individual therapy (Cercek and 
Saltz, 2008). 
1.3 Tumor angiogenesis 
1.3.1 Physiologic and pathologic angiogenesis 
Angiogenesis or neovascularization is the multistep physiological process of 
generating new blood vessels from pre-existing vasculature. It is an essential 
requirement for normal physiological conditions such as the process during the 
development of the organs in new-borns, during wound healing, vascular system in 
embryonic development of the placenta during pregnancy and for the reproductive 
function of adults (Tonnesen et al., 2000; Auerbach et al., 2003; Sagar et al., 2006). 
Nevertheless, angiogenesis play fundamental role in numerous pathologic disorders 
of many diseases, such as rheumatoid arthritis, psoriasis, cardiovascular, blindness, 
obesity, ischemia, cornel neovascularisation, diabetic retinopathy, tumor growth, 
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tumor propagation, metastasis formation and inflammatory diseases (Folkman, 1971; 
Folkman, 1995; Auerbach et al., 2003; Hanyu et al., 2009; Prager et al., 2011;).           
In 2004, Hoeben and others reported angiogenesis in adults as being tightly 
controlled by a physiological balance between the stimulatory (pro-angiogenic) and 
inhibitory (anti-angiogenic) signals.  
Several studies reported that angiogenesis may be an excellent therapeutic 
target for the treatment of tumor and other angiogenesis dependent disease (Ferrara, 
2002; Carmeliet, 2005). Therfore, insufficiency of angiogenesis may occur in 
reduction the tumor growth, invasion and metastasis (Folkman, 1974; Chia et al., 
2010).  
Therapeutically, targeting angiogenesis has been widely regarded as an 
attractive approach for cancer therapy (Hoeben et al., 2004). For that reason, 
determining the pro-angiogenic or anti-angiogenic effects of the molecules currently 
used in cancer treatment is crucial (Folkman, 1971; Carmeliet, 2005). 
1.3.2 Angiogenesis cascade events 
Angiogenesis depends on the interactions of the endothelial cell with the 
extracellular matrix compounds. There are multistep processes to develop effective 
angiogenesis. Regulated steps, which involve the formation of blood vessels, are 
initiation by biological signals, which lead to the activation of the receptors on the 
endothelial cell by the angiogenic growth factors (Gupta and Qin, 2003). The 
activated cells, which cover the blood vessel walls, start to release proteases enzymes 
(Matrix Metalloproteinase such as MMP9) that cause pericytes to detach and degrade 
the extracellular matrix and basement membrane, which allows the underlying 
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endothelial cells to escape from the blood vessel walls. Following this, the front lines 
of endothelial cells migrate toward the angiogenic stimulus (Fischer et al., 2006). 
The migrating cells start proliferation to form solid sprouts that link to adjacent 
vessels using adhesion molecules called integrins.  
The sprouts fuse with other sprouts to form loops. The new blood vessels 
formed are lined by vascular basal lamina. Finally, blood starts to flow through the 
new vessels (Eliceiri and Cheresh, 2001; Hoeben et al., 2004). Targeting any of these 
steps can inhibit the formation of new blood vessels, thus it could be striking 
approach for treating angiogenesis-related diseases, most notably cancer (Cardenas et 
al., 2011) (Figure1.3). 
 
Figure ‎1.3: Angiogenesis Cascade. (a): Blood vessels (b): Pericytes (PC) detach, 
blood vessels dilate before basement membrane (BM) and extracellular matrix 
(ESM) gets degraded (c) The underlying endothelial cells escape from the blood 
vessels wallto allows endothelial cells (EC) to migrate into perivascular space 
towards angiogenic stimuli, (d) after that, the endothelial cells proliferate, following 
each other, guided by pericytes, (e) endothelial cells adhere to each other and formed 
a lumen which is accompanied by basement membrane formation and attachment by 
pericytes. Finally, the blood vessels sproutingfuse with other sprouts to form loops 
which formation of new circulatory systems. Adapted from (Bergers & Benjamin 
2003). 
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1.3.3 Regulation of angiogenesis 
Angiogenesis is tightly regulated process that controlled by balance between 
pro-angiogenic (stimulators) and anti-angiogenic (inhibitors) molecules. In their 
review article, Liekens and his co-workers narrate the angiogenesis process in three 
steps: the first step is the degradation of the extracellular matrix, the second is the 
regulation of angiogenic modulators, including the growth factors and the cytokines 
and enzymes, and the third level is the cell-cell and the cell-matrix interactions 
(Liekens et al., 2001).  
The first step in the formation of new vessels is the proteolytic breakdown of 
the basement membrane underlying endothelial cells, in order for them to migrate 
and invade the stroma of surrounding tissues. This process requires the activity of the 
plasminogen activators (PAs) and the matrix metalloproteinase MMPs (Mignatti and 
Rifkin, 1996). The activity of both PAs and MMPs is controlled either at their 
expression level, at the activation level by the proteolytic enzymes, or at the level of 
their inhibitors, such as the tissue inhibitor of metalloproteinase and the plasminogen 
activator inhibitors (Liekens et al., 2001). 
Subsequent to the proteolytic degradation of the extracellular matrix and under 
the influence of a variety of growth factors, the frontline endothelial cells start to 
proliferate and migrate through the degraded matrix towards angiogenesis stimuli 
Several modulators of angiogenesis, including inducers and inhibitors, have been 
described so far: the vascular endothelial growth factor (VEGF), fibroblast growth 
factor-2 (FGF-2), the angiopoietins 1 and 2 (Ang-1 and 2), angiostatin, endostatin, 
interferons α and γ (IFN-α and γ) and several other growth factors (Liekens et al., 
2001). The regulation of angiogenesis depends on the balance between the 
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stimulators and inhibitors of the process; when the pro-angiogenic growth factors 
predominate, then proliferation and migration of endothelial cells is increased and 
this consequently leads to the formation of new blood vessels and angiogenesis can 
be halt when anti-angiogenic modulators dominate pro-angiogenic mediators (Table 
1.3). The cell adhesion molecules, besides the proteases enzymes and growth factors, 
play a critical role in the regulation of the angiogenesis cascade of events.  
Cell adhesion molecules are classified into four families such as 
immunoglobulin supergene family, cadherins, and the integrins. The integrins, for 
example, mediate the interaction of endothelial cells with the extracellular matrix 
during invasion and migration. Also, the cell adhesion molecules are required for 
cell–cell and cell– extracellular matrix interactions, which are required for lumen 
formation and the construction of functional capillary loops (Bischoff, 1997).  
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Table ‎1.3: Example of pro and anti-angiogenic factors. 
Pro-angiogenic (stimulators) Anti-angiogenic (Inhibitors) 
VEGF Interferons a/b  
bFGF/aFGF Canstatin 
PDGF VEGI 
PIGF Tumstatin 
TGFα/β Angiostatin 
Del-1  IL-12 
TNF-a  Vasostatin 
IL-8  Platelet factor-4  
HGF  Thrombospondin 
PD-ECGF  Endostatin 
Angiogenin 16-kd prolactin fragment  
IL-3  PEDF  
Midkine 2 methoxyestradiol 
Leptin  53-kd antithrombin III  
Follistatin Prothrombin fragments 1 and 2  
G-CSF Domain 5 of HMWK  
Proliferin Restin 
Pleiotrophin Maspin 
HIV Tat  SPARC  
Plasminogen activators, MMPs IP-10  
---- IL-18  
Abbreviations: FGF, fibroblast growth factor; PlGF, placental growth factor; PDGF, 
platelet-derived growth factor; TGF, transforming growth factor; Del-1, 
developmental endothelial locus-1; TNF-α, tumor necrosis factor alfa; VEGI, 
vascular endothelial growth inhibitor; IL, interleukin; HGF, hepatocyte growth 
factor; PD-ECGF, platelet-derived endothelial cell growth factor; PEDF, pigment 
epithelium-derived factor; HMWK, high molecular weight kininigen; G-CSF, 
granulocyte colony-stimulating factor; HIV Tat, human immunodeficiency virus 
TAT; IP-10, interferon-inducible protein-10; SPARC, secreted protein acidic and 
rich in cysteine. 
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1.3.4 Anti-angiogenic targets 
The formation of new blood vessels is a complicated multistep process. 
Agents that suppress or stop neovascularization often do so by interfering with an 
essential step in this process, such as: (a) Reduction of endothelial cell activation, 
which may be achieved via the inhibition of growth factor signal production, 
inhibition of receptors production or inhibition of the binding between signals and 
receptors, (b) Targeting of endothelial cell proliferation, (c) inhibition of endothelial 
cell migration, (d) inhibition of endothelial cell differentiation to form a three 
dimensional tube-like structure and (e) stimulation of apoptosis in endothelial cells 
(Zhang and Bicknell, 2001). 
1.3.5  Anti-angiogenic therapies 
Angiogenesis is the hallmark of cancer, which plays an important role in 
tumor growth, invasion, and metastasis, so blockade of angiogenesis has been 
viewed as an effective strategy for the therapy of tumor growth and progression. 
Therefore, targeting angiogenesis became of great therapeutic value to cancer and 
other angiogenesis related diseases, it work by starving the tumor and suppress its 
growth rather than targeting neoplasic cells (Folkman, 1971; Quesada et al., 2006).  
There are several current strategies for the inhibition of angiogenesis, which 
include antisense mRNA, monoclonal antibodies, receptor antagonists, and soluble 
receptors. More than forty anti-angiogenic drugs are being tested in human cancer 
patients in clinical trials all over the world. These can be divided into three groups 
according to the target point. The first group includes drugs that inhibit the growth of 
endothelial cells, such as endostatin and combretastatin A4, which induce the 
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apoptosis of endothelial cells (Kerbel and Folkman, 2002), whereas curcumin is an 
inhibitor of proliferation and cell cycle progression of endothelial cell (Singh et al., 
1996). The second group includes drugs that block angiogenesis signaling, such as 
Avastin
®
 and Interferon-alpha, which inhibits the production of basic fibroblast 
growth factor (b-FGF) and VEGF (Zhang and Bicknell, 2003). The third group 
consists of drugs that block extracellular matrix breakdown, such as inhibitors of 
matrix metalloproteinase (MMPs) and Pericytes (PC), which work by inhibiting the 
breakdown of extracellular matrix and thus interfere with the invasion and migration 
of endothelial cells.  
Other new drugs, such as the tyrosine kinase inhibitors (Erlotinib, Sorafenib 
and Sunitinib) block the activity of multiple growth factor receptors, such as VEGF 
and platelet-derived growth factor receptors (PDGFRs) (Tabernero, 2007; Gotink 
and Verheul, 2010). Currently, seventeen anti-angiogenic agents have been approved 
as anti-cancer therapies by the American Food and Drug Administration (FDA) 
(Bodnar, 2014) (Table 1.4). These include small molecule tyrosine kinase inhibitors 
directed against pro-angiogenic growth factor receptors and monoclonal antibodies 
directed against specific pro-angiogenic growth factors or their receptors (Samant 
and Shevde, 2011; Bodnar, 2014). 
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Table ‎1.4: FDA-approved angiogenesis inhibitors (Adapted from Bodnar, 2014) 
Inhibitor  Trade name 
(manufacturer)  
Type of drug  Target Clinical usage 
Bevacizumab  Avastin 
(Genentech 
Monoclonal 
antibody 
VEGFR1–
2 tyrosine 
kinase 
Metastatic CRC, 
NSCLC,glioblastoma, 
metastatic RCC 
Cetuximab Erbitux (Bristol-
Myers Squibb) 
 Monoclonal 
antibody 
EGFR 
tyrosine 
kinase 
Metastatic CRC, 
RCC 
Panitumumab Vecitbix (Amgen) Monoclonal 
antibody 
EGFR  Metastatic CRC 
RanibizumabLucentis (Genentech) Monoclonal 
antibody 
VEGF-A Wet age-related 
macular degeneration 
Trastuzumab Herceptin 
(Genentech) 
Monoclonal 
antibody 
HER2 Advanced RCC 
(Axitinib Inlytan (Pfizer) Small-molecule 
inhibitor 
VEGFR1–
3 
Advanced RCC 
Cabozantinib Cometriq 
(Exelixis) 
Small-molecule 
inhibitor 
VEGFR2 c-Met Metastatic 
medullary thyroid 
cancer 
Erlotinib Tarceva 
(Genentech) 
Small-molecule 
inhibitor 
EGFR 
tyrosine 
kinase 
Advanced or 
metastatic NSCLC 
Everolimus Afinitor (Novartis) Small-molecule 
inhibitor 
mTOR, 
PI3/AKT 
pathway 
Advanced 
RCC,pancreatic 
neuroendrocrintumor, 
SEGA 
Imiquimod Aldara (Medicis) Small-molecule 
inhibitor 
TLR-7 Actinic keratosis, 
basal cell carcinoma 
Pazopanib Votrient 
(GlaxoSmithKline) 
Small-molecule 
inhibitor 
VEGFR, 
PDGFR, c-
Kit 
Advanced RCC 
Regorafenib Stivarga (Bayer) Small-molecule 
inhibitor 
VEGFR1–
3, PDGFR, 
FGFR, Kit, 
Raf, RET 
Metastatic CRC 
Sunitinib Sutent (Pfizer) Small-molecule 
inhibitor 
VEGFR1–
3, 
PDGFRb, 
RET 
Advanced RCC, 
GIST, pancreatic 
neuroendocrine tumor 
Sorafenib Nexavar 
(Bayer/Onyx) 
Small-molecule 
inhibitor 
VEGFR1–
3,PDGFRb, 
Raf-1 
Advanced RCC, 
advanced HCC 
Temsirolimus Torisel (Wyeth) Small-molecule 
inhibitor 
mTOR Advanced RCC 
Vandetanib Caprelsa 
(AstraZeneca) 
Small-molecule 
inhibitor 
VEGFR, 
FGFR 
Medullary thyroid 
cancer 
Pegabtanib Macugen (OSI 
Pharmaceuticals) 
Pegylatedaptamer VEGF Wet age-related 
macular degeneration 
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1.4 Correlation between cancer and angiogenesis 
1.4.1 Pro and anti-angiogenic mediators 
Pro-angiogenic factors are one of the most critical tumor markers that play an 
important role in neoplastic transformation and the progression of microvessel 
growth in cancer. It is initiated by the secretion of growth factors with angiogenic 
properties, such as vascular endothelial growth factor (VEGF), transforming growth 
factor-α (TGF-α), basic fibroblast growth factor (b-FGF) and epidermal growth 
factor (EGF), nerve growth factor (NGF) platelet-derived growth factor (PDGF), 
Interleukin 1, 2 &7, Interferon (IFNs) and Granulocyte macrophage colony 
stimulating factor (GM CSF), (Prager et al., 2011). These growth factors stimulate 
angiogenesis via the binding to their relevant receptors which are mainly expressed 
in endothelial cells (Figure 1.4). 
Figure ‎1.4: Growth factors receptors. 
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 Vascular endothelial growth factor 1.4.1.(a)
VEGFA is the prototype member of a gene family that also includes VEGFB, 
VEGFC, VEGFD and placenta growth factor (PLGF) (Figg and Folkman, 2008). It is 
a dimeric glycoprotein that binds strongly with vascular endothelial cell receptors 
called VEGF receptor-2 (VEGFR-2), which is a member of a receptor tyrosine 
kinase family (Shibuya, 2011).This is an important protein involved in developing      
a new blood supply, like the formation of new blood vessels from pre-existing ones 
(angiogenesis) and the formation of new blood vessels from non-pre-existing ones 
(vasculogenesis). In addition to a secreted endothelial-specific growth factor that is 
strongly VEGFR-2-implicated in all aspects of pathological vascular-endothelial-cell 
biology, dimerization of the receptor is followed by autophosphorylation, which 
leads to the activation of the angiogenic cascade (Olsson et al., 2006; Koch and 
Claesson-Welsh, 2012). Since, a close relationship between several pathologies and 
angiogenesis has been clarified; various angiogenic inhibitors have been studied. 
Many of these inhibitors are directed against VEGF or its receptors, which are 
considered to play a key role in angiogenesis (Niu and Chen, 2010). Thus targeting 
angiogenesis could be a strategy to combat angiogenesis-dependent diseases. In the 
case of cancer, most tumors require a more extensive blood supply to provide 
nutrition in order to support rapid growth (Veeravagu et al., 2007; Wang et al., 
2015). 
 Hypoxia inducible factor-1 1.4.1.(b)
Hypoxia inducible factor-1 (HIF-1) is a transcription factor which plays critical 
role in the regulation of multiple aspects of tumorigenesis such as nutritional stress, 
